Skip to search formSkip to main contentSkip to account menu

67Ga-DOTATOC

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Biokinetic and dosimetry of 90y-dotatoc therapy for neuroendocrine tumours
Biokinetic model is a mathematical model which desc ribes the behavior of the Y in human body during the treatment of neuroendocr… 
2011
2011
Monitoring of perfusion changes after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy using contrast-enhanced ultrasound in liver metastatic neuroendocrine…
2011
2011
Intraarterial Treatment of GEP NET: 68Ga-DOTATOC SUV Cannot Predict 90Y-DOTATOC Uptake
Kratochwil and colleagues ([1][1]) demonstrate in their very elegant study that selective intraarterial (i.a.) application of… 
2011
2011
Nierenfunktion und Peptid-Rezeptor-Radionuklid-Therapie (PRRT)
Zusammenfassung Die Radionuklidrezeptortherapie (PRRT) mit 90-Yttrium oder 177-Lutetium gekoppelten Somatostatinanaloga ist eine… 
2009
2009
Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with YDOTATOC and Lu-DOTATATE is promising. The kidney is… 
2009
2009
Apparent diffusion coefficient predicts biochemical response in neuroendocrine liver metastases treated using targeted radiolabelled therapy
Introduction: Y-DOTATyr3octreotide (Y-DOTATOC) therapy targets tumour cells expressing somatostatin receptors and induces tumour… 
2000
2000
Tyr 3 -octreotide ( 90 Y-DOTATOC), a Radiolabelled Somatostatin Analogue
The case history is presented of a patient with paraplegia caused by progressive spinal cord compression due to bone metastases…